Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 39 min 12 sec ago

FUJIFILM VisualSonics Introduces Vevo LAZR-X, Next Generation In Vivo Multi-Modal Imaging Platform

39 min 12 sec ago
TORONTO--(BUSINESS WIRE)--FUJIFILM VisualSonics Inc., a world leader in ultra high frequency ultrasound and photoacoustic imaging systems and subsidiary of FUJIFILM SonoSite, Inc., today announced the launch of its new Vevo LAZR-X, the world’s only customizable imaging platform combining ultra high frequency ultrasound and photoacoustics for animal research applications. Featuring superior image resolution—down to 30 microns—the Vevo LAZR-X was designed for a variety of translational research a

Philips Joins the Mackenzie Innovation Institute (Mi2) Mission to Develop Disruptive Innovations and Solutions That Improve Patient Care

1 hour 39 min ago
MARKHAM, Ontario--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it is partnering with the Mackenzie Innovation Institute (Mi2) in Canada on opportunities to develop, test and evaluate technological solutions and innovations intended to improve patient care across the healthcare system. “Truly innovative patient centred solutions require collaboration between technology leaders like Philips and healthcare innovators,” said Altaf Stationwala, President and CEO, Macken

Certara Strategic Consulting Awarded Good Laboratory Practices (GLP) Compliant Toxicokinetic Test Site Certification

1 hour 39 min ago
PRINCETON, N.J.--(BUSINESS WIRE)--Certara, a drug development tech and consulting company, today announced that the Standards Council of Canada has awarded Good Laboratory Practices certification to its Montreal office.

Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017

Tue, 21/02/2017 - 09:44
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am. Eastern time:       Toll Free: 1-877-876-9174   Access Code: 57368   The purpose of the conference call will be to provide investors with an update on the Company’s initiatives an

New Report: Newcomers to Canada Need Ways to Show Skills to Biotech Employers

Tue, 21/02/2017 - 09:44
OTTAWA, Ontario--(BUSINESS WIRE)--#Cdnimm--Paving the Way, a labour market report on internationally educated professionals in Canada's biotechnology sector, was released today by BioTalent Canada.

Antibe Therapeutics Engages MKR Group for U.S. Investor Relations

Mon, 20/02/2017 - 18:37
TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Engages MKR Group for U.S. Investor Relations

Enigma Biomedical Group Signs Research Agreement with McGill University Research Centre for Studies in Aging

Mon, 20/02/2017 - 16:36
TORONTO--(BUSINESS WIRE)--Enigma Biomedical Group today announced a clinical research agreement with McGill University Research Centre for Studies in Aging in Montreal to support multiple projects over the next several years. These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a ha

Health Canada Approves Otsuka and Lundbeck's REXULTI™ (brexpiprazole) as a Treatment for Schizophrenia in Adults

Fri, 17/02/2017 - 17:08
TOKYO & MONTREAL--(BUSINESS WIRE)--Health Canada Approves Otsuka and Lundbeck's REXULTI™ (brexpiprazole) as a Treatment for Schizophrenia

Appili Therapeutics Awarded $2.8M From ACOA to Fund Clinical Trials

Fri, 17/02/2017 - 14:06
HALIFAX, Nova Scotia--(BUSINESS WIRE)--#ACOA--Appili Therapeutics will be receiving $2.8 M from ACOA. These funds will assist with taking its first drug, a taste-masked, oral antibiotic for anaerobic infections through clinical trials.

CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement for Cannabis Orally Dissolvable Thin Film (ODF) Wafer

Fri, 17/02/2017 - 09:04
SASKATOON, Saskatchewan & STONEY CREEK, Ontario--(BUSINESS WIRE)--CTT Pharmaceutical Holdings and CanniMed Therapeutics Inc. Complete Exclusive Canadian Licensing Agreement for Cannabis Orally Dissolvable Thin Film (ODF) Wafer

Innomar Strategies Enhances Market Access Expertise with Acquisition of Wyatt Health Management

Thu, 16/02/2017 - 09:58
OAKVILLE, Ontario--(BUSINESS WIRE)--Innomar Strategies, Canada’s leading specialty pharmaceuticals service provider and a part of AmerisourceBergen, announced today the acquisition of Wyatt Health Management.

Zymeworks Receives Second Orphan Drug Designation for ZW25 in Gastric Cancer

Thu, 16/02/2017 - 05:56
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer, today announced that its lead product candidate, ZW25, has been granted orphan drug designation from the U.S. Food and Drug Administration (the “FDA”) in the treatment of gastric cancer, including cancer of the gastroesophageal ju

Global Next-Generation Sequencing Market (Forecast: 2016–2021) – Top-Down Analytics

Wed, 15/02/2017 - 10:53
LOS ANGELES--(BUSINESS WIRE)--#NGS--Top-Down Analytics, a Los Angeles-based market research and management consulting firm has announced its new report entitled “The Global Next Generation Sequencing, Forecast 2016–2021.”

Generex Announces Elimination of Outstanding Derivative Securities

Wed, 15/02/2017 - 09:53
MIRAMAR, Fla. & TORONTO--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities. This is an important milestone for the Company. The consequent reduction in the number of shares coming into the market and the termination of the attendant price protection provisions will unburden the Company. In addition, the elimination of the derivative liability will greatly improve the Company’s balance s

Ferring Announces Recipients of Innovation Grants Program 2016-2017

Wed, 15/02/2017 - 08:52
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring today announced the recipients of the 2016-2017 Ferring Innovation Grants program, an annual initiative of the Ferring Research Institute (FRI) which provides grants of up to $100,000 for early stage research. The program focuses on novel extracellular drug targets addressable with peptides or proteins within Ferring’s core therapeutic areas: reproductive health, gastroenterology, urology, and endocrinology. The 2016-2017 awardees and their rese

Masimo Announces CE Marking of Respiration Rate Measurement on MightySat™ Rx

Wed, 15/02/2017 - 08:52
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo announced today the CE marking of the measurement of respiration rate from the pleth (RRp™) on the MightySat™ Rx fingertip pulse oximeter.

Versant Ventures Launches Jecure Therapeutics

Wed, 15/02/2017 - 08:52
SAN DIEGO--(BUSINESS WIRE)--Versant Ventures today announced the debut of Jecure Therapeutics, a biotechnology company with a proprietary liver disease platform that has generated novel programs for non-alcoholic steatohepatitis (NASH) and fibrosis. Versant seeded Jecure as part of the firm’s push to build on its past success in the fibrosis field, and was the sole investor in today’s $20 million series A commitment. Jecure’s founding team includes CEO Jeffrey Stafford, PhD, and CSO James Veal,

Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium

Tue, 14/02/2017 - 17:47
CHARLESTON, S.C.--(BUSINESS WIRE)--#2017GenitourinaryCancersSymposium--Aeterna Zentaris Announces Zoptrex™ in Prostate Cancer at 2017 Genitourinary Cancers Symposium

Trial Underway to Provide Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of Multiple Sclerosis (MS)-Induced Neuropathic Pain

Tue, 14/02/2017 - 07:42
SASKATOON, Saskatchewan & WINNIPEG, Manitoba--(BUSINESS WIRE)--Studying Scientific Validity of the Analgesic Efficacy and Safety of Medical Cannabis in an Experimental Autoimmune Encephalomyelitis (EAE) Animal Model of MS

Aurinia Announces Results from Japanese Phase I Ethnic Bridging Study for Voclosporin

Tue, 14/02/2017 - 07:42
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the results of a supportive Phase I safety, pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy Japanese patients which supports further development of voclosporin in this patient population. Based on evaluations comparing the Japanese ethno-bridging data vs

Pages